仁和藥業(000650.SZ):與關聯方叮噹快藥籤訂產品網絡總經銷協議、商標授權使用協議
格隆匯 7 月 7日丨仁和藥業(000650.SZ)公佈,公司與關聯方叮噹快藥科技集團有限公司(含所有控股的子、孫公司)(“叮噹快藥”)簽訂《產品網絡總經銷協議》《商標授權使用協議》。
為了更好利用和進一步整合公司與叮噹快藥雙方現有資源,快速提升公司產品銷售渠道,提升公司商標的知名度和美譽度,公司就叮噹快藥作為公司產品網絡經銷商,負責公司產品的網上銷售、推廣工作,以及就“婦炎潔”、“伊康美寶”、“優卡丹”、“米阿卡”等商標,在公司暫不生產該商標的產品類別上授權許可叮噹快藥使用達成一致。2020年下半年預計關聯交易金額9590萬元人民幣。
叮噹快藥與公司的關係為同一最終控制方,根據深圳證券交易所《股票上市規則》及《公司章程》的規定,交易構成關聯交易,但不構成重大關聯交易,也未構成《上市公司重大資產重組管理辦法》規定的重大資產重組,應提交董事會審議,無需提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.